ArticleJACC. Case reports2025
A Case of Cutaneous Kaposi Sarcoma in a Patient Post-Heart Transplantation.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HHV-8 Infection in Solid-Organ Transplant-Pathogenesis, Epidemiology, Clinical Manifestations and Management.Reviews in medical virology · 2026Review
- Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough patients with solid organ transplants have a higher risk of developing Kaposi sarcoma (KS), the data on KS post-heart transplantation are sparse. CASE SUMMARY: We present a case of a 69-year-old man with a history of heart transplantation for ischemic cardiomyopathy who developed violaceous skin lesions 5 months after transplant, with a skin biopsy confirming human herpesvirus-8-positive KS. Given no extracutaneous involvement, he was managed with a modification in his immunosuppressive regimen, with initiation of sirolimus and reduction in his tacrolimus dosage, as well as with topical imiquimod and local radiation. DISCUSSION: Although KS in other solid organ transplants, namely kidney, has been well documented, guidance on how to manage KS in post-heart transplant is lacking. TAKE-HOME MESSAGE: This case illustrates that a mammalian target of rapamycin inhibitor-based immunosuppressive regimen and locoregional therapy may be an effective strategy to manage post-heart transplantation cutaneous KS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.